UY39529A - Nuevos agentes antivirales derivados de espiropirrolidina - Google Patents

Nuevos agentes antivirales derivados de espiropirrolidina

Info

Publication number
UY39529A
UY39529A UY0001039529A UY39529A UY39529A UY 39529 A UY39529 A UY 39529A UY 0001039529 A UY0001039529 A UY 0001039529A UY 39529 A UY39529 A UY 39529A UY 39529 A UY39529 A UY 39529A
Authority
UY
Uruguay
Prior art keywords
spiropyrrolidine
formula
pharmaceutically acceptable
antiviral agents
agents derived
Prior art date
Application number
UY0001039529A
Other languages
English (en)
Inventor
Xuri Gao
Xiaowen Peng
Wei Li
Hui Cao
Samuel Bartlett
Yong He
Xuechao Xing
Ruichao Shen
Jiang Long
Jun Ma
Jiajun Zhang
Joseph D Panarese
Nathaniel Thomas Kenton
Yat Sun Or
Guoqiang Wang
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/479,244 external-priority patent/US11384090B2/en
Priority claimed from US17/479,530 external-priority patent/US11352363B1/en
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of UY39529A publication Critical patent/UY39529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención revela compuestos de Fórmula (Ia), y sales de uso farmacéutico aceptable de los mismos que inhiben la actividad de replicación de coronavirus. La invención además se relaciona a composiciones farmacéuticas que comprenden un compuesto de Fórmula (Ia) o una sal de uso farmacéutico aceptable del mismo, y métodos de tratamiento o prevención de una infección por coronavirus en un sujeto que lo necesita, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de Fórmula (Ia) o una sal de uso farmacéutico aceptable del mismo.
UY0001039529A 2020-11-23 2021-11-22 Nuevos agentes antivirales derivados de espiropirrolidina UY39529A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063117170P 2020-11-23 2020-11-23
US202163142663P 2021-01-28 2021-01-28
US17/479,244 US11384090B2 (en) 2020-11-23 2021-09-20 Spiropyrrolidine derived antiviral agents
US17/479,530 US11352363B1 (en) 2020-11-23 2021-09-20 Spiropyrrolidine derived antiviral agents

Publications (1)

Publication Number Publication Date
UY39529A true UY39529A (es) 2022-06-30

Family

ID=78725298

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039529A UY39529A (es) 2020-11-23 2021-11-22 Nuevos agentes antivirales derivados de espiropirrolidina

Country Status (13)

Country Link
EP (1) EP4001279A1 (es)
JP (1) JP2023551174A (es)
KR (1) KR20230124582A (es)
CN (1) CN114524821A (es)
AU (1) AU2021381437A1 (es)
CA (1) CA3173333A1 (es)
CL (1) CL2023001476A1 (es)
CO (1) CO2023008018A2 (es)
IL (1) IL302991A (es)
MX (1) MX2023005984A (es)
TW (1) TW202237616A (es)
UY (1) UY39529A (es)
WO (1) WO2022109363A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022109360A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
WO2023086400A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023109926A1 (zh) * 2021-12-17 2023-06-22 南京药石科技股份有限公司 螺环氧化吲哚类化合物及其用于制备抗病毒蛋白酶抑制剂药物的用途
US12006291B2 (en) 2022-01-11 2024-06-11 Enanta Pharmaceuticals, Inc. Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid
US20230295175A1 (en) * 2022-03-18 2023-09-21 Enanta Pharmaceuticals, Inc. Processes for the preparation of substituted spirooxindole derivatives
CN116621918B (zh) * 2022-07-20 2023-10-31 深圳信立泰药业股份有限公司 一种螺环化合物及其制备方法与应用
CN115466189B (zh) * 2022-09-19 2024-08-30 安徽普利药业有限公司 一种氨基酸及其衍生物的纯化方法
WO2024076680A1 (en) * 2022-10-06 2024-04-11 Enanta Pharmaceuticals, Inc. Crystal forms of an anti-sars cov-2 agent
CN115894504A (zh) * 2022-10-21 2023-04-04 深圳信立泰药业股份有限公司 一种冠状病毒3cl蛋白酶抑制剂及其用途
US20240199647A1 (en) * 2022-11-02 2024-06-20 Aligos Therapeutics, Inc. Anti-viral compounds
CN117986260A (zh) * 2022-11-03 2024-05-07 中国科学院上海药物研究所 一类螺环化合物、其制备方法及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
EP1628674A2 (en) 2003-05-06 2006-03-01 Cytovia, Inc. Protease inhibitors for coronaviruses and sars-cov and the use thereof
WO2004101781A1 (en) 2003-05-13 2004-11-25 Universität Zu Lübeck Crystal structure of human coronavirus 229e main proteinase, and uses thereof for developing sars inhibitors
US20060014821A1 (en) 2003-08-27 2006-01-19 Agouron Pharmaceuticals, Inc. Inhibitors of SARS 3C like protease
US7462594B2 (en) 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
WO2005113580A1 (en) 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WO2006061714A2 (en) 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
MY160077A (en) * 2011-01-21 2017-02-15 Univ Sains Malaysia Curcumin compounds and their preparations thereof
EP2760827A4 (en) 2011-09-27 2015-06-24 Univ Kansas State ANTIVIRAL MEDIUM WITH A WIDE SPECTRUM AGAINST 3C OR 3C-SIMILAR PROTEASES FROM PICORNIVIRUS SUPERCLUSTS: PICORNIVERS, CALICIVIRES AND CORONA VIRUSES
WO2013166319A1 (en) 2012-05-02 2013-11-07 Kansas State University Research Foundation Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses
WO2017222935A1 (en) * 2016-06-20 2017-12-28 Kansas State University Research Foundation Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses
US11033600B2 (en) 2016-07-28 2021-06-15 Kansas State University Research Foundation Protease transition state inhibitor prodrugs
TW201817714A (zh) 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 抑制3c及3cl蛋白酶之化合物及其使用方法

Also Published As

Publication number Publication date
TW202237616A (zh) 2022-10-01
CA3173333A1 (en) 2022-05-27
AU2021381437A9 (en) 2024-10-10
CL2023001476A1 (es) 2023-12-11
KR20230124582A (ko) 2023-08-25
JP2023551174A (ja) 2023-12-07
CN114524821A (zh) 2022-05-24
MX2023005984A (es) 2023-08-17
AU2021381437A1 (en) 2023-06-22
CO2023008018A2 (es) 2023-07-10
IL302991A (en) 2023-07-01
EP4001279A1 (en) 2022-05-25
WO2022109363A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
UY39529A (es) Nuevos agentes antivirales derivados de espiropirrolidina
CL2023000167A1 (es) Péptidos funcionalizados como agentes antivirales
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
SA521430792B1 (ar) مركبات مضادة للفيروسات محتوية على نيتريل
MX2022012714A (es) Inhibidores de la replicacion de norovirus y coronavirus.
UY37998A (es) Agentes antivirales contra la hepatitis b
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
RU2013121788A (ru) Ингибиторы репликации вич
EA200702445A1 (ru) Соединения тиазола и способы их применения
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
UY38614A (es) Derivados de benzodiazepinas como inhibidores del rsv
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
CL2022002588A1 (es) Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica.
MX2024001540A (es) Inhibidores para coronavirus.
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
AR126501A1 (es) Nuevos agentes antivirales derivados de espiropirrolidina
AR126482A1 (es) Agentes antivirales derivados de espiropirrolidina
UY39642A (es) Compuestos heterocíclicos antivirales
MX2024001377A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
AR129003A1 (es) Compuestos heterocíclicos antivirales
AR122280A1 (es) Compuestos heterocíclicos antivirales
AR118379A1 (es) Derivados de benzodiazepinas como inhibidores del rsv